BCG Immunotherapy in Patients With Malignant Melanoma

Archives of Surgery

Volumn 111, Issue 6, 1976, Pages 716-718

  Karakousis, Constantine P ^a   Douglass, Harold O ^a   Yeracaris, Peter M ^a   Holyoke, Edward D ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; BCG VACCINE;

CANCER IMMUNOTHERAPY; IMMUNOTHERAPY; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MELANOMA; THEORETICAL STUDY; THERAPY;

BCG VACCINE; HUMAN; IMMUNOTHERAPY; INJECTIONS, INTRADERMAL; LYMPH NODE EXCISION; MELANOMA; MYCOBACTERIUM BOVIS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; SKIN NEOPLASMS; TUBERCULIN TEST;

EID: 0017059770     PISSN: 00040010     EISSN: 15383644     Source Type: Journal    
DOI: 10.1001/archsurg.1976.01360240096018     Document Type: Article

References (16)

1. Gold P, Freedman SO: Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 121:439-462, 1965.
2. Seigler HF, Kremer WB, Metzgar RS, et al: HL-A antigenic loss in malignant transformation. J Natl Cancer Inst 46:577-584, 1971.
3. Graham JB, Graham RM: Autogenous vaccine in cancer patients. Surg Gynecol Obstet 114:1-4, 1962.
4. Cunningham TJ, Olson KB, Laffin R, et al: Treatment of advanced cancer with active immunization. Cancer 24:932-937, 1969.
5. Ikonopisov RL, Lewis MG, Hunter-Craig ID, et al: Autoimmunization with irradiated tumor cells in human malignant melanoma. Br Med J 2:752-754, 1970.
6. Currie GA, Lejeune F, Hamilton-Fairley G: Immunization with irradiated tumor cells and specific lymphocyte cytotoxicity in malignant melanoma. Br Med J 2:305-310, 1971.
7. Old LJ, Benacerraf B, Clarke DA, et al: The role of the reticuloendothelial system in the host reaction to neoplasia. Cancer Res 21:1281-1300, 1961.
8. Mathe G, Auriel JL, Schwarzenberg L, et al: Active immunotherapy for acute lymphoblastic leukemia. Lancet 2:677-699, 1969.
9. Bluming AZ, Vogel CL, Ziegler JL, et al: Immunological effects of BCG in malignant melanoma: Two modes of administration compared. Ann Intern Med 76:405-411, 1972.
10. Levy NL: Letter to the editor. Int J Cancer 11:497, 1973.
11. Clark WH Jr, From L, Bernardino EA, et al: The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 29:705-726, 1969.
12. Gutterman JU, McBride C, Freireich EJ, et al: Active immunotherapy with BCG for recurrent malignant melanoma. Lancet 1:1208-1212, 1973.
13. Morton DL, Eilber FR, Holmes EC, et al: BCG immunotherapy of malignant melanoma: Summary of a seven-year experience. Ann Surg 180:635-643, 1974.
14. Morton DL, Crispen RG, in discussion, Makhann C, Gunnarsson A: Immunotherapy of melanoma with BCG: A fatality following intralesional injection, in Crispen RG (ed): Neoplasm Immunity: BCG Vaccination; A Chicago Symposium, 1973. Chicago, Institute for Tuberculosis Research, University of Illinois, 1974, pp 42-43.
15. Seigler HF, Shingleton WW, Metzgar RS, et al: Nonspecific and specific immunotherapy in patients with melanoma. Surgery 72:162-174, 1972.
16. Bast RC Jr, Zbar B, Borsos T, et al: BCG and Cancer. N Engl J Med 290:1413-1420, 1458-1469, 1974.